Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin dose-escalation study in pediatric acute heart failure
2013-002847-28Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serelaxin in Acute Heart Failure (AHF), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Apr 2014; status: terminated.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2013-002847-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002847-28.